Tango Therapeutics director proposes $183K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
John Ketchum, a director of Tango Therapeutics, Inc. (TNGX), filed notice of a proposed sale of 7,590 common shares, with an aggregate market value of $183,450.30 and an approximate sale date of November 17, 2026. The shares were acquired through restricted stock unit vesting from August 19, 2024, through August 17, 2026.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date is listed for John Ketchum’s proposed TNGX sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.